Methods and findings

This cohort study included all Stockholm residents aged 45 or older (N = 963,876), followed up from 1 March 2020 until 11 November 2020. The exposure was statin treatment initiated before the COVID-19-pandemic, defined as recorded statin dispensation in the Swedish Prescribed Drug Register between 1 March 2019 and 29 February 2020. COVID-19-specific mortality was ascertained from the Swedish Cause of Death Registry. Hazard ratios (HRs) were calculated using multivariable Cox regression models. We further performed a target trial emulation restricted to initiators of statins.

In the cohort (51.6% female), 169,642 individuals (17.6%) were statin users. Statin users were older (71.0 versus 58.0 years), more likely to be male (53.3% versus 46.7%), more often diagnosed with comorbidities (for example, ischemic heart disease 23.3% versus 1.6%), more frequently on anticoagulant and antihypertensive treatments, less likely to have a university-level education (34.5% versus 45.4%), and more likely to have a low disposable income (20.6% versus 25.2%), but less likely to reside in crowded housing (6.1% versus 10.3%).

A total of 2,545 individuals died from COVID-19 during follow-up, including 765 (0.5%) of the statin users and 1,780 (0.2%) of the nonusers. Statin treatment was associated with a lowered COVID-19 mortality (adjusted HR, 0.88; 95% CI, 0.79 to 0.97, P = 0.01), and this association did not vary appreciably across age groups, sexes, or COVID-19 risk groups. The confounder adjusted HR for statin treatment initiators was 0.78 (95% CI, 0.59 to 1.05, P = 0.10) in the emulated target trial. Limitations of this study include the observational design, reliance on dispensation data, and the inability to study specific drug regimens.

Author summary


The Coronavirus Disease 2019 (COVID-19) pandemic continues to evolve. Vaccines are underway, and possible treatments are being tested in trials and clinics. The understanding of the pathophysiology of the disease continues to grow along with the knowledge of risk factors for severe COVID-19 disease and death. Hyperinflammation and hypercoagulability have been identified as central to the development of severe COVID-19 disease and complications [14]. Hence, drugs that modulate the host immune response and inhibit thrombosis and vascular dysfunction have received widespread attention. Special attention has been given to low-risk and low-cost treatments that can be easily administered across different settings [515].

Lipid-lowering HMG-CoA reductase inhibitors (statins), which are used in vast groups of patients for the prevention and treatment of cardiovascular diseases, are one of the pharmaceutical classes that have been proposed as possible preventive and/or adjuvant treatment of severe COVID-19. In brief, statins inhibit the enzyme HMG-CoA reductase central to the endogenous synthesis of cholesterol. This inhibition results in decreased levels of harmful LDL cholesterol in blood plasma. Statins are also known to have pleiotropic effects, including immune modulation, decreased inflammation in blood vessels, improved endothelial function, decreased thrombocyte aggregation, decreased risk of thrombosis, increased fibrinolysis, and stabilization of atherosclerotic plaques [1618].

Several observational studies have investigated statins and report, with some discrepancies, an association between statin use and decreased COVID-19 mortality [1927]. However, many previous studies have failed to avoid the potential pitfalls of observational studies, like those commonly described under the emulated trial framework [28]. In addition, most previous studies have had small sample sizes, owing to the fact that they have been based on early pandemic cases, and often included only hospitalized populations. As such, a recently published meta-analysis showed substantial heterogeneity (i2 90%) between previous studies, likely due to methodological discrepancies [29]. For example, certain studies of statins and COVID-19 mortality have suggested a substantial excessive risk (odds ratio (OR) 6.21), while others have suggested implausible benefits (OR 0.46) [29].

Pending ongoing clinical trials [3038], we present a large population-based observational study using Swedish health register data, with the aim of determining the relationship between statin treatment and COVID-19 mortality, scrutinize if this relationship is robust to target trial emulation of statin initiation and examine whether such a relationship is consistent across age groups, sexes, and COVID-19 risk groups.


Study design and data sources

We designed a total population study, covering all Stockholm residents meeting the study criteria (see below), based on routinely collected data from the following registries: the longitudinal integrated database for health insurance and labor market studies (LISA) [39] for information on education and income, the VAL databases of Region Stockholm containing information from both hospitals and outpatient clinics on preexisting conditions according to the International Classification of Diseases (ICD), as well as data from the Swedish Prescribed Drug Register [40] on collected prescriptions coded by anatomical therapeutic classification (ATC) codes. Data on COVID-19 related deaths were collected from the Swedish Cause of Death Registry [41]. Registries and records were linked through the personal identity number assigned to each Swedish resident [42]. The study has been approved by the Regional Ethical Review Board, Stockholm (2021–00810). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 STROBE Checklist).

Statistical analysis

Using measures of central tendency and dispersion, we descriptively presented our sample by statin exposure. To quantify the relationship between statin treatment and COVID-19-specific mortality, we employed cause-specific Cox regression, using days since 1 March 2020 as the underlying timescale.

We present unadjusted and adjusted hazard ratios (HRs) and their 95% confidence intervals, adjusting for sex (categorical), age (continuous), country of birth (categorical), the highest level of obtained education (categorical), annual disposable income in 2018 (quartiles), residential area (categorical), household crowding (m2 per person) (deciles), nursing home (yes/no), exposure to angiotensin-converting enzyme (ACE) inhibitors (yes/no), angiotensin receptor blockers (yes/no), and anticoagulants (yes/no) as well as a broad range of conditions (yes/no); atrial fibrillation, cancer, cerebrovascular disorders, chronic kidney disease, chronic lower respiratory disease, dementia (inc. Alzheimer disease), type 1 and type 2 diabetes, dyslipidemia, heart failure, hypertension, ischemic heart disease, obesity, other neurological conditions, peripheral vascular disease, pure hypercholesterolemia, renal failure stage 3 to 5, stroke and transient ischemic attack (TIA), and vascular disease (see S1 Table for ICD-10/ATC codes).

We evaluated the proportional hazard assumption by testing the slope of the Martingale residuals as well as through visual inspection of log of minus log plots, finding limited evidence of a violation of the proportional hazard assumption. As the fraction of residents with missing covariate information was small (6.2%), all analyses were performed using the so-called missing indicator approach, where residents with missing covariate information are treated as a distinct category in each covariate. We repeated our main analysis using complete case, to examine a possible difference compared to the missing indicator approach.

Subgroup analyses were performed for age groups, sexes, different statin indications as well as COVID-19 risk groups (identified by authorities and/or in previous studies on risk factors [43]), and evaluated for heterogeneity using the Cochran’s Q statistic. Computations were performed using SAS version 9.4. P values <0.05 were considered statistically significant.

The rapid development of the COVID-19 pandemic prevented us from preregistering our statistical analysis plan, as we prioritized a rapid execution of our study.

Sensitivity analyses

We performed several sensitivity analyses to scrutinize our results: We (1) restricted our main analysis to statin initiators (emulating a target trial with an intention-to-treat analysis [44]); (2) repeated the main analysis with COVID-19 as the main underlying cause of death as the outcome measure; (3) performed analysis of all-cause mortality without COVID-19 (positive outcome analysis [45]); and (4) performed our main analysis using the Fine-Gray method for competing risks [46], treating non-COVID deaths as competing events.


Main analysis of COVID-19 mortality

A total of 2,545 individuals died from COVID-19 during follow-up, including 765 (0.5%) of the statin users and 1,780 (0.2%) of the nonusers (unadjusted HR, 2.02; 95% CI, 1.85 to 2.20) (Fig 1). However, when adjusting for confounders, statin treatment was associated with a moderately lower risk of COVID-19 mortality (HR, 0.88; 95% CI, 0.79 to 0.97). This association was similar across age groups (P = 0.821) and sexes (P = 0.657) and COVID-19 risk groups/indications for statin treatment (P = 0.727).


Fig 1. HRs of death from COVID-19 in relation to dispensations of statins overall and the HRs of death from COVID-19 in relation to dispensations of statins within strata of age, sex, and within COVID-19 risk groups.

chr, chronic; CI, confidence interval; COVID-19, Coronavirus Disease 2019; HR, hazard ratio; TIA, transient ischemic attack.


Sensitivity analyses

In our emulated target trial (statin initiators only), the negative association between statin treatment and COVID-19 mortality remained but was not statistically significant (HR, 0.78; 95% CI, 0.59 to 1.05) (S1 Text). Restricting our analysis to those with COVID-19 as the main underlying cause of death did not alter our findings (S1 Text). Our positive outcome analysis was consistent with a protective effect of statins (as expected), although the estimated protective effect was greater than that of meta-analysis of randomized controlled trials examining statins for primary prevention in high-risk populations [47] (S1 Text). The fact that we were able to replicate the known association between statin treatment and reduced (overall) mortality gives further support for the validity of the results from our COVID-19 analysis. There was no difference between our main analysis and a complete case replication of our analysis (HR, 0.87; 95% CI, 0.79 to 0.97, N = 903,782). There was no difference between our main analysis and when treating non-COVID deaths as competing events using the Fine–Gray method (adjusted HR, 0.88; 95% CI, 0.80 to 0.98) (S2 Table).


Interpretation of results

In this register-based cohort study of 963,876 Stockholm residents aged 45 or older, statin treatment was associated with a moderately lower risk of COVID-19 mortality. Adjusted HRs were largely consistent across age groups, sexes, as well as across different COVID-19 risk groups and indications for statin treatment. This result was corroborated by our sensitivity analysis explicitly emulating a target trial among initiators of statin treatment.

Several cohort studies of hospitalized COVID-19 patients have reported negative associations between statin use and mortality [2027], in line with our findings. These studies have been summarized in meta-analyses indicating an overall reduction of unfavorable COVID-19 outcomes (including death, intensive care unit (ICU) admission, and mechanical ventilation) of about 30% in statin users [48,49]. The meta-analyses also demonstrate substantial heterogeneity between studies (i2 90%) [29], and a recent large-scale study on severe COVID-19 and all-cause mortality in COVID-19–positive Danish citizens showed no association between statin use and either outcome [19].

Existing studies have been limited in their appreciation of the complexity of causal inference when using observational data and may thus be prone to the critical pitfalls of observational studies of clinical interventions. Such pitfalls have, for example, been clearly demonstrated in works on statins and cancer [28] and, indeed, in studies of COVID-19 [50]. These include failure to differentiate between new and prevalent users (leading to survival bias), using post-baseline information to establish exposure (leading to immortal time bias), introducing collider bias by sampling only hospitalized patients and/or conditioning on positive PCR test results or adjusting for potential mediators (such as disease severity).

Strengths and limitations

Our study has several strengths. Most importantly, we applied a rigorous methodological approach to avoid the potential biases mentioned above, resulting in a study with high internal validity. To avoid conditioning on PCR testing, which may introduce collider bias (as previously observed in connection with COVID-19 research [50]), the outcome measure was based on data from The Swedish Cause of Death Register. This register contains all deaths determined by physicians to be caused (in full or in part) by COVID-19, based on testing or other diagnostics. Moreover, mortality carries a smaller risk of selection bias than outcome measures such as ICU admission or severity of disease.

Furthermore, we were able to control for a large set of important confounders using data collected in a standardized manner. We also avoid confounding that may arise from altered behavior during the COVID-19 pandemic. Specifically, the end of the period of exposure was set to 1 March 2020—the start of the pandemic in Stockholm—since the collection of prescriptions during a pandemic could be a proxy for certain behaviors affecting the risk of exposure to the virus (for example, the frequenting of public spaces). While we believe that this is a major strength of our study, such time restrictions imply that we include statin dispensations, which, in theory, could have been collected long before a COVID-19 infection. Indeed, individuals who collect a sole prescription in early 2019 will be classified as exposed. However, this is in line with the intention-to-treat principle. As such, our estimate may represent a conservative estimate of the causal effect of statins on COVID-19 mortality; our estimate can be interpreted as that obtained from an observational intention-to-treat analysis in the presence of noncompliance, which we believe is the clinically relevant causal contrast. Another important aspect is the differentiation in recommendations for different age groups during spring and summer; people aged 70 or older were recommended to isolate, which could render analyses based on dispensation during the spring and summer unrecoverable from such selection mechanisms.

Lastly, in context of other evidence on COVID-19, the duration of follow-up is long and the number of exposed cases high. Our study includes the total population of Stockholm County, whereas most previous studies were hospital-based. Hence, the results are likely to have higher external validity.

However, the study also has several important limitations. Firstly, as in any observational study, residual confounding cannot be ruled out. For example, we have not adjusted for smoking or body mass index (BMI), but only diagnosed obesity. Both smoking and high BMI are strongly linked to statin use [51], and high BMI has been identified as a risk factor for COVID-19 death [52]. Although we would expect this to result in an underestimation of a potential protective effect, we cannot dismiss the possibility that our findings may be explained by confounding.

Secondly, as in most pharmacoepidemiological studies, we have assumed that drug dispensation captures drug use correctly. This assumption is easily challenged since not all patients filling prescriptions adhere to treatment. This misclassification is, however, unlikely to explain our findings. Any nondifferential misclassification will generally dilute associations, and we judge a possible differential misclassification to bias our findings toward a positive association if adherence is particularly low in severely ill patients (including in COVID-19) or patients that have low health literacy and fewer means of avoiding the infection.

Lastly, we have not been able to study possible effects of dosage, type, or brand of statins. Specifically, despite our study being, the hereby largest study of statins and COVID-19 mortality, we had an insufficient sample size to perform such granular analysis. As such, our estimate should be interpreted as the mean of possibly heterogeneous effects.

Further aspects should be considered when interpreting our findings. This study does not concern the possible effect of statin treatment for treatment of severe COVID-19, but its possible preventive effect. Furthermore, although our duration of follow-up is longer than comparable studies, future studies could shed light on the long-term effects of statins on COVID-19 mortality and possible heterogeneity in effects over subsequent COVID-19 waves. Although we emulated a target trial with an intention-to-treat analysis, the study does not provide an analysis of the risk of adverse events in potential target groups. Safety evaluations are outside the scope of the current study as they require extensive clinical and qualitative safety data, and such evaluations should address several aspects of the overall concept of statin safety. Nonetheless, this has been addressed in previous clinical trials, but not in connection with this new potential indication (COVID-19 prevention). Although statins are considered to have a favorable safety profile [53] compared to many other drug classes discussed in connection with COVID-19, a clinical risk assessment must always be made. Finally, although our study has greater generalizability due to the general population design (as compared to hospital-based studies), its results should be interpreted in light of the Swedish COVID-19 strategy, which may have implications for the generalizability of our findings.


The current pandemic constitutes a unique situation in that policy and treatment decisions are being continuously made on the basis of limited knowledge. In the absence of results from randomized clinical trials [3038], our study can provide some guidance. Specifically, it gives further support for continuing statin treatment for conditions such as cardiovascular disease and hyperlipidemia, in line with current recommendations [5457], during the COVID-19 pandemic.


  1. 1.
    Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036–45.e9. pmid:32416070
  2. 2.
    Rodriguez L, Pekkarinen PT, Lakshmikanth T, Tan Z, Consiglio CR, Pou C, et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Rep Med. 2020;1(5):100078.
  3. 3.
    Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–32. pmid:32651579
  4. 4.
    Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. 2020;8(12):1201–8. pmid:32861276
  5. 5.
    Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;19(7):102569. pmid:32376394
  6. 6.
    Castiglione V, Chiriaco M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):258–9. pmid:32347925
  7. 7.
    Fajgenbaum DC, Rader DJ. Teaching Old Drugs New Tricks: Statins for COVID-19? Cell Metab. 2020;32(2):145–7. pmid:32755604
  8. 8.
    Fecchi K, Anticoli S, Peruzzu D, Iessi E, Gagliardi MC, Matarrese P, et al. Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. Front Microbiol. 2020;11:1821. pmid:32849425
  9. 9.
    Fedson DS, Opal SM, Rordam OM. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. mBio. 2020;11(2). pmid:32198163
  10. 10.
    Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020;113(7):509–10. pmid:32219440
  11. 11.
    Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. Int J Infect Dis. 2020;96:615–7. pmid:32502659
  12. 12.
    Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight. Drug Dev Res. 2020;81(5):541–3. pmid:32227357
  13. 13.
    Reiner Z, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–6. pmid:32399094
  14. 14.
    Rodrigues-Diez RR, Tejera-Munoz A, Marquez-Exposito L, Rayego-Mateos S, Santos Sanchez L, Marchant V, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020;177(21):4873–86. pmid:32562276
  15. 15.
    Teoh N, Farrell G. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome—time is of the essence. J Clin Transl Res. 2020;5(5):227–9. pmid:32617428
  16. 16.
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47. pmid:3513311
  17. 17.
    Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. pmid:15822172
  18. 18.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–65. pmid:11430324
  19. 19.
    Butt JH, Gerds TA, Schou M, Kragholm K, Phelps M, Havers-Borgersen E, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ Open. 2020;10(12):e044421. pmid:33277291
  20. 20.
    Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020;136:149–55. pmid:32946859
  21. 21.
    De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G, Belmans L, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc. 2020;21(7):909–14.e2. pmid:32674818
  22. 22.
    Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, et al. Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19. Res Sq. 2020. pmid:32818209
  23. 23.
    Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24(1):429. pmid:32664990
  24. 24.
    Song SL, Hays SB, Panton CE, Mylona EK, Kalligeros M, Shehadeh F, et al. Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. Pathogens. 2020;9(9). pmid:32957539
  25. 25.
    Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176–87.e4. pmid:32592657
  26. 26.
    Nicholson CJ, Wooster L, Sigurslid HH, Li RF, Jiang W, Tian W, et al. Estimating Risk of Mechanical Ventilation and Mortality Among Adult COVID-19 patients Admitted to Mass General Brigham: The VICE and DICE Scores [preprint]. medRxiv. 2020. pmid:32995802
  27. 27.
    Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran. Tohoku J Exp Med. 2020;252(1):73–84. pmid:32908083
  28. 28.
    Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601–6. pmid:31591592
  29. 29.
    Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis. 2021. pmid:33838992
  30. 30.
    Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP). [updated 2020 Oct 12. ClinicalTrials.gov identifier: NCT02735707.]. https://www.clinicaltrials.gov/ct2/show/NCT02735707.
  31. 31.
    Atorvastatin as Adjunctive Therapy in COVID-19 (STATCO19) [updated 2021 Mar 19. ClinicalTrials.gov identifier: NCT04380402.]. https://www.clinicaltrials.gov/ct2/show/NCT04380402.
  32. 32.
    Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial (COLSTAT). NIH; [updated 2021 Mar 2. ClinicalTrials.gov identifier: NCT04472611.]. https://www.clinicaltrials.gov/ct2/show/NCT04472611.
  33. 33.
    Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (INTENSE-COV). [updated 2021 Feb 4. ClinicalTrials.gov identifier: NCT04466241.]. https://www.clinicaltrials.gov/ct2/show/NCT04466241.
  34. 34.
    Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia.: NIH; [updated 2021 Feb 8. ClinicalTrials.gov identifier: NCT04359095.]. https://www.clinicaltrials.gov/ct2/show/NCT04359095.
  35. 35.
    Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 (INSPIRATION). ClinicalTrials.gov: NIH; [updated 2021 Feb 9. https://www.clinicaltrials.gov/ct2/show/NCT04486508.
  36. 36.
    Managing Endothelial Dysfunction in COVID-19: A Randomized Controlled Trial at LAUMC (MEDIC-LAUMC). ClinicalTrials.gov: NIH; [updated 2021 Mar 29. https://www.clinicaltrials.gov/ct2/show/NCT04631536.
  37. 37.
    Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial (C-19-ACS). ClinicalTrials.gov [updated 2020 Apr 9. ClinicalTrials.gov identifier: NCT04333407.]. https://www.clinicaltrials.gov/ct2/show/NCT04333407.
  38. 38.
    Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19 (Ruxo-Sim-20). ClinicalTrials.gov [updated 2020 Apr 17. ClinicalTrials.gov identifier: NCT04348695.]. https://clinicaltrials.gov/ct2/show/NCT04348695.
  39. 39.
    Ludvigsson JF, Svedberg P, Olen O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–37. pmid:30929112
  40. 40.
    Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35. pmid:16897791
  41. 41.
    Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–73. pmid:28983736
  42. 42.
    Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67. pmid:19504049
  43. 43.
    National Center for Immunization and Respiratory Diseases. People at increased Risk: People with Certain Medical Conditions. 2020 [updated 2021 Mar 15]. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.
  44. 44.
    Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183(8):758–64. pmid:26994063
  45. 45.
    Tchetgen ET. The control outcome calibration approach for causal inference with unobserved confounding. Am J Epidemiol. 2014;179(5):633–40. pmid:24363326
  46. 46.
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
  47. 47.
    Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–31. pmid:20585067
  48. 48.
    Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol. 2020;134:153–5. pmid:32891399
  49. 49.
    Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab. 2020;47(6):101220. pmid:33359486
  50. 50.
    Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11(1):5749. pmid:33184277
  51. 51.
    Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation. 2009;120(5):384–90. pmid:19620502
  52. 52.
    Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. Endocrinol Diabetes Metab. 2020:e00176. pmid:32904932
  53. 53.
    Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182–4. pmid:33196154
  54. 54.
    Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
  55. 55.
    Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350. pmid:30423393
  56. 56.
    Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(19):1997–2007. pmid:27838723
  57. 57.
    National Institute for Health and Clinical Excellence. Guidance: Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Clinical Excellence: Guidance. London: National Clinical Guideline Centre (UK); 2014.

Source link